If approved, NS Pharma’s viltolarsen would be the first drug to treat children born with Duchenne muscular dystrophy. Barring any problems, the drug could be approved by the agency by mid-2020 or sooner, though the agency has not yet set an approval decision date, according to STAT.
Sarepta aimed to release its drug, Vyondys 53, earlier this year, but it was rejected by the FDA in August due to safety concerns, including the risk of infections and kidney toxicity seen in animal experiments.
Sarepta has not yet announced a plan to address the FDA’s concerns about its drug, but said it plans to meet with the FDA before the end of the year, according to STAT.
Sarepta’s stock price has plummeted this year because of concern over its relationship with the FDA. Investors are also concerned manufacturing challenges have caused the drugmaker to delay development of its muscular dystrophy treatment.
Read the full article here.
More articles on pharmacy:
Following CVS, Walgreens and Rite Aid pull Zantac from shelves
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
